Source study found

Story checked

How insurance coverage shapes access to kidney transplantation (opens in a new tab)

medicalxpress.com · 2026-10-29

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

How insurance coverage shapes access to kidney transplantation

medicalxpress.com · 2026-10-29

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

3 supported
2 not covered

Open claim evidence

The source study

Medicare Advantage Enrollment and Access to Kidney Transplant After the 21st Century Cures Act

JAMA · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe Brown University–led study examined 630,848 Medicare beneficiaries with end-stage kidney disease from 2021 through 2023.View evidenceHide evidence

As stated630,848 beneficiaries; 2021 through 2023

Why this verdict

The cohort size, ESKD population, Medicare beneficiary population, and 2021-2023 period are supported by the abstract-profile. However, the specific attribution that the study was “Brown University–led” is not present in the supplied paper profile and cannot be verified at this depth.

Study evidence

Overall adjusted transplant rate was lower among Medicare Advantage beneficiaries compared with traditional Medicare beneficiaries.2.51 vs 4.60 per 1000 person-months; aRR 0.71 (95% CI, 0.69–0.72)

“Retrospective cohort study of Medicare beneficiaries aged 18 to 74 years with ESKD... from January 1, 2021, through December 31, 2023.”

Claim 2 of 5Not coveredAlthough the findings do not establish that Medicare Advantage caused the differences, they support closer monitoring of transplant access and further examination of potential barriers, including provider networks and prior authorization.View evidenceHide evidence

Why this verdict

The noncausal caveat is supported by the observational retrospective design and limitations. The abstract-profile also supports concern about access differences. However, the recommendation for closer monitoring and the named potential mechanisms—provider networks and prior authorization—are not documented in the supplied abstract-level profile, so those parts are not verifiable at this depth.

Study evidence

Overall adjusted transplant rate was lower among Medicare Advantage beneficiaries compared with traditional Medicare beneficiaries.2.51 vs 4.60 per 1000 person-months; aRR 0.71 (95% CI, 0.69–0.72)

“Retrospective cohort study of Medicare beneficiaries aged 18 to 74 years with ESKD... from January 1, 2021, through December 31, 2023.”

Study evidence

Incident (new) kidney transplant wait-listing was lower among Medicare Advantage enrollees compared with traditional Medicare enrollees during 2021–2023: 3.05 vs 4.64 per 1000 person-months; adjusted rate ratio 0.77 (95% CI, 0.75–0.78).aRR 0.77 (95% CI, 0.75–0.78); rates 3.05 vs 4.64 per 1000 person-months

“The secondary outcome was incident (new) wait-listing.”

Claim 3 of 5SupportedA study published in JAMA raises questions about whether patients have comparable access across Medicare coverage options.View evidenceHide evidence

Why this verdict

The abstract-profile frames the study as comparing Medicare Advantage vs traditional Medicare among beneficiaries with ESKD after the 2021 eligibility expansion and reports lower adjusted transplant and incident wait-listing rates in Medicare Advantage. The story’s hedged phrasing about questions of comparable access is consistent with the observational evidence.

Study evidence

Overall adjusted transplant rate was lower among Medicare Advantage beneficiaries compared with traditional Medicare beneficiaries.2.51 vs 4.60 per 1000 person-months; aRR 0.71 (95% CI, 0.69–0.72)

“Retrospective cohort study of Medicare beneficiaries aged 18 to 74 years with ESKD... from January 1, 2021, through December 31, 2023.”

Study evidence

“The secondary outcome was incident (new) wait-listing.”

Claim 4 of 5SupportedAfter adjusting for measured differences between patients, researchers found that Medicare Advantage enrollees had a 29% lower rate of kidney transplantation and a 23% lower rate of being newly placed on a transplant waiting list than traditional Medicare beneficiaries.View evidenceHide evidence

As stated29% lower rate of kidney transplantation; 23% lower rate of new waitlisting

Why this verdict

The abstract-profile reports adjusted rate ratios of 0.71 for transplant and 0.77 for incident wait-listing among Medicare Advantage vs traditional Medicare beneficiaries, corresponding to 29% and 23% lower adjusted rates, respectively. The claim accurately presents these as adjusted comparative findings rather than causal effects.

Study evidence

Overall adjusted transplant rate was lower among Medicare Advantage beneficiaries compared with traditional Medicare beneficiaries.2.51 vs 4.60 per 1000 person-months; aRR 0.71 (95% CI, 0.69–0.72)

“Retrospective cohort study of Medicare beneficiaries aged 18 to 74 years with ESKD... from January 1, 2021, through December 31, 2023.”

Study evidence

“The secondary outcome was incident (new) wait-listing.”

Claim 5 of 5SupportedThe study followed a federal policy change that expanded Medicare Advantage eligibility for people with end-stage kidney disease in 2021.View evidenceHide evidence

As stated2021 policy change

Why this verdict

The profile states that the 21st Century Cures Act expanded Medicare Advantage eligibility for people with ESKD and that the study examined the first three years after that policy change, 2021-2023.

Study evidence

Overall adjusted transplant rate was lower among Medicare Advantage beneficiaries compared with traditional Medicare beneficiaries.2.51 vs 4.60 per 1000 person-months; aRR 0.71 (95% CI, 0.69–0.72)

“Retrospective cohort study of Medicare beneficiaries aged 18 to 74 years with ESKD... from January 1, 2021, through December 31, 2023.”

Study evidence

“The secondary outcome was incident (new) wait-listing.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Conditional analysis among beneficiaries wait-listed at baseline or during follow-up found lower transplant rates for Medicare Advantage enrollees, but with a smaller adjusted difference: aRR 0.91.
The story does not mention the wait-listed subgroup analysis, which is a distinct paper finding and materially narrows one interpretation of where differences may occur.
From Retrospective cohort subanalysis (wait-listed subgroup)
Administrative/claims-data limitations, including possible outcome or covariate misclassification and limited clinical detail, are noted in the profile limitations.
The story’s caveats do not mention administrative-data limitations or possible misclassification.
From Retrospective cohort (administrative claims-based); Retrospective cohort (secondary data); Retrospective cohort subanaly
Cohort restriction to beneficiaries aged 18-74 limits generalizability.
The story states Medicare beneficiaries with ESKD but omits the age range restriction reported in the profile.
From Retrospective cohort (administrative claims-based); Retrospective cohort (secondary data); Retrospective cohort subanaly
Subgroup and temporal findings: transplant-rate differences were widest among younger beneficiaries aged 18-44 and adjusted rate ratios were stable across 2021, 2022, and 2023.
The story does not discuss age-stratified results or year-specific stability.
From Retrospective cohort (administrative claims-based)

5 things the story did carry across

Retrospective observational cohort design using Medicare beneficiaries with ESKD, comparing Medicare Advantage with traditional Medicare during 2021-2023.
Primary outcome: kidney transplant rates were lower among Medicare Advantage beneficiaries than traditional Medicare beneficiaries after adjustment, with aRR 0.71.
Secondary outcome: incident new wait-listing rates were lower among Medicare Advantage beneficiaries than traditional Medicare beneficiaries, with aRR 0.77.
Causal inference limitation: the study is retrospective and observational, with potential residual confounding despite adjustment.
Findings reflect only the early post–21st Century Cures Act period, 2021-2023, and may not represent longer-term trends.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataCompare kidney transplant rates between Medicare Advantage vs traditional Medicare beneficiaries with ESKD during 2021-2023 (post–21st Century Cures Act period).Retrospective cohort (administrative claims-based)Expand

In plain English

Retrospective cohort study of Medicare beneficiaries with end-stage kidney disease (age 18–74) from 2021–2023 comparing kidney transplant receipt between Medicare Advantage and traditional Medicare enrollees. Over ~14.8 million person-months, Medicare Advantage enrollees had lower transplant and incident wait-listing rates than traditional Medicare after multivariable adjustment; results were consistent across calendar years and were most pronounced among younger beneficiaries.

Key findings

Overall adjusted transplant rate was lower among Medicare Advantage beneficiaries compared with traditional Medicare beneficiaries.2.51 vs 4.60 per 1000 person-months; aRR 0.71 (95% CI, 0.69–0.72)
Incident wait-listing rates were lower for Medicare Advantage enrollees compared with traditional Medicare enrollees.3.05 vs 4.64 per 1000 person-months; aRR 0.77 (95% CI, 0.75–0.78)

“Retrospective cohort study of Medicare beneficiaries aged 18 to 74 years with ESKD... from January 1, 2021, through December 31, 2023.”

What this piece can’t prove

Retrospective observational design using administrative/claims data (limits on causal inference and potential for residual confounding).
Abstract provides limited methodological detail (variable definitions, handling of missing data, and additional sensitivity analyses not reported).
Cohort restricted to beneficiaries aged 18–74 and to the period 2021–2023; findings reflect early post–21st Century Cures Act years and may not represent longer-term trends.

2secondary dataCompare incident (new) wait-listing rates between Medicare Advantage vs traditional Medicare beneficiaries with ESKD during 2021-2023.Retrospective cohort (secondary data)Expand

In plain English

In a retrospective cohort of Medicare beneficiaries aged 18–74 with end-stage kidney disease (ESKD) from 2021–2023, incident (new) placement on the kidney transplant wait list was lower among Medicare Advantage enrollees than among traditional Medicare enrollees (3.05 vs 4.64 per 1000 person-months), with an adjusted rate ratio of 0.77 (95% CI, 0.75–0.78). Models adjusted for demographics, dual Medicare–Medicaid eligibility, duration of ESKD, socioeconomic status, and hospital referral region.

Key findings

Incident (new) kidney transplant wait-listing was lower among Medicare Advantage enrollees compared with traditional Medicare enrollees during 2021–2023: 3.05 vs 4.64 per 1000 person-months; adjusted rate ratio 0.77 (95% CI, 0.75–0.78).aRR 0.77 (95% CI, 0.75–0.78); rates 3.05 vs 4.64 per 1000 person-months

“The secondary outcome was incident (new) wait-listing.”

What this piece can’t prove

Retrospective observational design; associations may be affected by residual confounding not accounted for by adjusted covariates.
Administrative/claims-based ascertainment of wait-listing may misclassify outcomes or omit clinical detail.
Analysis restricted to beneficiaries aged 18–74 and to the first three years after the policy change (2021–2023), which may limit generalizability and capture only early-period effects.

3secondary dataAmong beneficiaries who were wait-listed at baseline or became wait-listed during follow-up, compare subsequent transplant rates by Medicare Advantage vs traditional Medicare.Retrospective cohort subanalysis (wait-listed subgroup)Expand

In plain English

Subgroup analysis restricted to beneficiaries who were wait-listed at baseline or were placed on a transplant wait list during follow-up. Among this wait-listed subgroup, Medicare Advantage enrollees had lower observed transplant incidence and a modestly lower adjusted transplant rate than traditional Medicare enrollees over 2021–2023.

Key findings

Among beneficiaries wait-listed at baseline or placed on a wait list during observation, Medicare Advantage enrollees had lower transplant incidence and a lower adjusted transplant rate than traditional Medicare enrollees.aRR 0.91 (95% CI, 0.90–0.92)

“Among beneficiaries wait-listed at baseline or placed on a wait list during observation, Medicare Advantage enrollees had lower transplant rates (16.59 vs 20.85 per 1000 person-months; aRR, 0.91; 95% CI, 0.90-0.92).”

What this piece can’t prove

Summary is based on abstract text only; full-paper methodological details (exact regression model, covariate measurement, follow-up handling) are not available here.
Results apply to Medicare beneficiaries aged 18–74 with ESKD during 2021–2023 and may not generalize beyond that population or time frame.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer